Sana Biotechnology, Inc.
$3.82
▲
4.92%
2026-04-21 09:17:01
www.sana.com
NMS: SANA
Explore Sana Biotechnology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$939.37 M
Current Price
$3.82
52W High / Low
$6.55 / $1.53
Stock P/E
—
Book Value
$0.6
Dividend Yield
—
ROCE
-60.83%
ROE
-1.19%
Face Value
—
EPS
$-0.96
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
142
Beta
2.06
Debt / Equity
53.62
Current Ratio
1.89
Quick Ratio
1.89
Forward P/E
-5.06
Price / Sales
—
Enterprise Value
$772.5 M
EV / EBITDA
-4.33
EV / Revenue
—
Rating
None
Target Price
$8.43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Apellis Pharmaceuticals, Inc. | $40.94 | 233.76 | $5.23 B | — | 7.37% | 7.48% | $40.95 / $16.1 | $2.92 |
| 2. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 3. | Alector, Inc. | $2.71 | — | $298.53 M | — | -69.73% | -1.82% | $3.4 / $0.9 | $0.28 |
| 4. | Tenaya Therapeutics, Inc. | $0.74 | — | $169.71 M | — | -70.98% | -83.84% | $2.35 / $0.36 | $0.57 |
| 5. | Compass Therapeutics, Inc. | $5.42 | — | $1.08 B | — | -35.42% | -41.29% | $6.88 / $1.6 | $1.1 |
| 6. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
| 7. | Turn Therapeutics Inc. | $3.38 | — | $103.07 M | — | -134.02% | -1.42% | $26.5 / $2.57 | $0.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -61.2 M | -43.52 M | -50.36 M | -50.63 M | -50.87 M |
| Net Profit | -58.83 M | -42.15 M | -93.8 M | -49.39 M | -49.07 M |
| EPS in Rs | -0.22 | -0.16 | -0.35 | -0.19 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -205.71 M | -270.83 M | -286.13 M | -272.56 M |
| Net Profit | -244.17 M | -266.76 M | -283.25 M | -269.48 M |
| EPS in Rs | -0.91 | -1 | -1.06 | -1.01 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 416.89 M | 501.02 M | 565.3 M | 822.72 M |
| Total Liabilities | 256.01 M | 250.52 M | 277.79 M | 323.4 M |
| Equity | 160.88 M | 250.5 M | 287.51 M | 499.31 M |
| Current Assets | 148.68 M | 160.81 M | 213.51 M | 444.44 M |
| Current Liabilities | 78.73 M | 45.43 M | 64.49 M | 111.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -143.83 M | -223.15 M | -253.58 M | -290.05 M |
| Investing CF | -40.24 M | 17.45 M | 172.01 M | 210.56 M |
| Financing CF | 128.73 M | 199.75 M | 31.65 M | 4.91 M |
| Free CF | -144.77 M | -256.58 M | -273.61 M | -310.93 M |
| Capex | -0.94 M | -33.43 M | -20.03 M | -20.88 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 5.82% | -5.11% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.